专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08993295B2 Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting 有权
标题翻译：通过组合靶向选择性活化原毒素的方法，组合物和试剂盒
公开(公告)号：US08993295B2
公开(公告)日：2015-03-31
申请号：US12374616
申请日：2007-07-20
申请人： Brian Seed , Jia Liu Wolfe , Glen S. Cho , Chia-Iun Tsai
发明人： Brian Seed , Jia Liu Wolfe , Glen S. Cho , Chia-Iun Tsai
IPC分类号： C12N9/96 , C07K16/28 , A61K47/48 , B82Y5/00 , C07K14/195 , C07K14/28 , C07K14/34 , C12N9/16 , A61K38/00
CPC分类号： C07K16/2803 , A61K38/00 , A61K47/6849 , A61K47/6889 , A61K47/6899 , B82Y5/00 , C07K14/195 , C07K14/28 , C07K14/34 , C07K2319/55 , C12N9/16 , Y02A50/471
摘要： The present invention provides methods and compositions for treating various diseases through selective killing of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.
摘要翻译：本发明提供了使用组合靶向方法通过选择性杀死靶细胞来治疗各种疾病的方法和组合物。本发明的特征在于含有细胞靶向部分的原毒素融合蛋白，以及由目标细胞内或其附近天然可操作地发现的活化部分活化的可修饰的活化部分。这些方法还包括组合使用两种或更多种治疗剂，至少包含原毒素和原毒素激活剂以靶向和破坏特定细胞群体。

2. 发明授权

US09340584B2 Engineered thioredoxin-like fold proteins 有权
标题翻译：工程硫氧还蛋白样折叠蛋白
公开(公告)号：US09340584B2
公开(公告)日：2016-05-17
申请号：US14006237
申请日：2012-03-29
申请人： Jia Liu Wolfe , Glen S. Cho , Brian Seed
发明人： Jia Liu Wolfe , Glen S. Cho , Brian Seed
IPC分类号： C07K14/01 , C12N15/10 , G01N33/68 , G01N33/53 , C07K14/00
CPC分类号： C07K14/001 , C07K2319/35 , C12N15/1044 , G01N33/53 , G01N33/68
摘要： The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins.
摘要翻译：本发明的特征在于基于硫氧还蛋白样折叠蛋白质结构域的组合物，其描述为工程化硫氧还蛋白样折叠蛋白（ETRX）。这些蛋白质包括一个或多个人工多样化的硫氧还蛋白样折叠蛋白质结构域; 每个结构域可以源于相同或不同的硫氧还蛋白样折叠蛋白结构域。本发明的特征还包括用于鉴定和制备具有额外序列变异的靶结合，环多样化ETRX的富集组合物以提高亲和力，稳定性，选择性或溶解度的方法。本发明还特征在于用补体基团，聚合物，蛋白质，核酸，碳水化合物，金属，天然或合成的小分子和毒素取代的ETRX的组合物。

3. 发明申请

US20140113832A1 ENGINEERED THIOREDOXIN-LIKE FOLD PROTEINS 有权
标题翻译：工程化的硫氧还蛋白样蛋白
公开(公告)号：US20140113832A1
公开(公告)日：2014-04-24
申请号：US14006237
申请日：2012-03-29
申请人： Jia Liu Wolfe , Glen S. Cho , Brian Seed
发明人： Jia Liu Wolfe , Glen S. Cho , Brian Seed
IPC分类号： C07K14/00 , G01N33/68
CPC分类号： C07K14/001 , C07K2319/35 , C12N15/1044 , G01N33/53 , G01N33/68
摘要： The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins.
摘要翻译：本发明的特征在于基于硫氧还蛋白样折叠蛋白质结构域的组合物，其描述为工程化硫氧还蛋白样折叠蛋白（ETRX）。这些蛋白质包括一个或多个人工多样化的硫氧还蛋白样折叠蛋白质结构域; 每个结构域可以源于相同或不同的硫氧还蛋白样折叠蛋白结构域。本发明的特征还包括用于鉴定和制备具有额外序列变异的靶结合，环多样化ETRX的富集组合物以提高亲和力，稳定性，选择性或溶解度的方法。本发明还特征在于用补体基团，聚合物，蛋白质，核酸，碳水化合物，金属，天然或合成的小分子和毒素取代的ETRX的组合物。

4. 发明申请

US20100055761A1 METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING 有权
标题翻译：通过组合靶向选择性激活原核生物的方法，组合物和试剂盒
公开(公告)号：US20100055761A1
公开(公告)日：2010-03-04
申请号：US12374616
申请日：2007-07-20
申请人： Brian Seed , Jia Liu Wolfe , Glen S. Cho , Chia-lun Tsai
发明人： Brian Seed , Jia Liu Wolfe , Glen S. Cho , Chia-lun Tsai
IPC分类号： C12N9/96
CPC分类号： C07K16/2803 , A61K38/00 , A61K47/6849 , A61K47/6889 , A61K47/6899 , B82Y5/00 , C07K14/195 , C07K14/28 , C07K14/34 , C07K2319/55 , C12N9/16 , Y02A50/471
摘要： The present invention provides methods and compositions for treating various diseases through selective killipg of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.
摘要翻译：本发明提供了使用组合靶向方法通过选择性杀死靶细胞来治疗各种疾病的方法和组合物。本发明的特征在于含有细胞靶向部分的原毒素融合蛋白，以及由目标细胞内或其附近天然可操作地发现的活化部分活化的可修饰的活化部分。这些方法还包括组合使用两种或更多种治疗剂，至少包含原毒素和原毒素激活剂以靶向和破坏特定细胞群体。

5. 发明授权

US08524241B2 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A 有权
标题翻译：包含霍乱弧菌外毒素A片段的融合蛋白
公开(公告)号：US08524241B2
公开(公告)日：2013-09-03
申请号：US12669712
申请日：2008-07-18
申请人： Brian Seed , Jia Liu Wolfe , Chia-Lun Tsai
发明人： Brian Seed , Jia Liu Wolfe , Chia-Lun Tsai
IPC分类号： C07K19/00 , C07K14/28 , C12P21/00 , C12N15/31 , C07H21/04
CPC分类号： C07K14/28
摘要： The invention features recombinant exotoxins from Vibrio cholerae are for the therapeutic treatment of a variety of human diseases, particularly diseases characterized by an abundance or excess of undesired cells.
摘要翻译：本发明特征在于来自霍乱弧菌的重组外毒素用于治疗各种人类疾病，特别是以不希望的细胞丰度或过量为特征的疾病。

6. 发明申请

US20100256070A1 RECOMBINANT VIBRIO CHOLERAE EXOTOXINS 有权
标题翻译：重组VIBRIO CHOLERAE EXOTOXINS
公开(公告)号：US20100256070A1
公开(公告)日：2010-10-07
申请号：US12669712
申请日：2008-07-18
申请人： Brian Seed , Jia Liu Wolfe , Chia-Lun Tsai
发明人： Brian Seed , Jia Liu Wolfe , Chia-Lun Tsai
IPC分类号： A61K38/16 , C07K14/28 , C07K19/00 , C12N15/63
CPC分类号： C07K14/28
摘要： The invention features recombinant exotoxins from Vibrio cholerae are for the therapeutic treatment of a variety of human diseases, particularly diseases characterized by an abundance or excess of undesired cells.
摘要翻译：本发明特征在于来自霍乱弧菌的重组外毒素用于治疗各种人类疾病，特别是以不希望的细胞丰度或过量为特征的疾病。

7. 发明授权

US08987323B2 Crystalline form of benzylbenzene SGLT2 inhibitor 有权
标题翻译：苄基苯SGLT2抑制剂的结晶形式
公开(公告)号：US08987323B2
公开(公告)日：2015-03-24
申请号：US13158724
申请日：2011-06-13
申请人： Mengzhuang Cai , Qian Liu , Ge Xu , Binhua Lv , Brian Seed , Jacques Y. Roberge
发明人： Mengzhuang Cai , Qian Liu , Ge Xu , Binhua Lv , Brian Seed , Jacques Y. Roberge
IPC分类号： A01N43/16 , A61K31/35 , A01N43/02 , A61K31/335 , A01N43/00 , A61K31/33 , C07D315/00 , C07D309/10
CPC分类号： C07H1/06 , C07D309/10 , C07H7/04
摘要： Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
摘要翻译：提供对钠依赖性葡萄糖转运体SGLT2具有抑制作用的化合物的结晶形式。本发明还提供药物组合物，制备结晶化合物的方法，以及独立地或与其它治疗剂组合使用结晶化合物治疗受SGLT或SGLT2抑制影响的疾病和病症的方法。

8. 发明授权

US08748419B2 Treating obesity with muscarinic receptor M1 antagonists 失效
标题翻译：用毒蕈碱受体M1拮抗剂治疗肥胖
公开(公告)号：US08748419B2
公开(公告)日：2014-06-10
申请号：US11763313
申请日：2007-06-14
申请人： Brian Seed , Jordan Mechanic
发明人： Brian Seed , Jordan Mechanic
IPC分类号： C07D487/04 , A61K31/55 , C07D333/20 , C07D307/80 , A61K31/135
CPC分类号： A61K31/343 , A61K31/135 , A61K31/137 , A61K31/381 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
摘要翻译：提供了通过施用优选的毒蕈碱性乙酰胆碱受体M1拮抗剂，任选地与选择性毒蕈碱性乙酰胆碱受体M1拮抗剂以外的至少一种抗抑郁药来治疗肥胖症并实现所需体重减轻或预防不希望的体重增加的方法。优选的毒蕈碱性乙酰胆碱受体M1拮抗剂，任选地可以与抗肥胖剂，例如无痛剂一起施用。本发明还提供用于至少一种选择性毒蕈碱性乙酰胆碱受体M1拮抗剂与除选择性毒蕈碱性乙酰胆碱受体M1拮抗剂之外的至少一种抗抑郁药组合的药物组合物和试剂盒。

9. 发明申请

US20120238510A1 CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR 有权
标题翻译：苯乙烯SGLT2抑制剂的结晶形式
公开(公告)号：US20120238510A1
公开(公告)日：2012-09-20
申请号：US13158724
申请日：2011-06-13
申请人： Mengzhuang Cai , Qian Liu , Ge Xu , Binhua Lv , Brian Seed , Jacques Y. Roberge
发明人： Mengzhuang Cai , Qian Liu , Ge Xu , Binhua Lv , Brian Seed , Jacques Y. Roberge
IPC分类号： A61K31/7034 , C07H1/06 , A61P3/10 , A61P5/48 , A61P3/00 , A61P35/00 , A61P7/00 , A61P3/04 , A61P7/10 , A61P3/06 , A61P9/04 , A61P9/10 , C07H7/04 , A61P9/12
CPC分类号： C07H1/06 , C07D309/10 , C07H7/04
摘要： Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
摘要翻译：提供对钠依赖性葡萄糖转运体SGLT2具有抑制作用的化合物的结晶形式。本发明还提供药物组合物，制备结晶化合物的方法，以及独立地或与其它治疗剂组合使用结晶化合物治疗受SGLT或SGLT2抑制影响的疾病和病症的方法。

10. 发明申请

US20080182802A1 SPIROHETEROCYCLIC GLYCOSIDES AND MEHTODS OF USE 有权
标题翻译：螺旋藻糖苷和使用的MEHTODS
公开(公告)号：US20080182802A1
公开(公告)日：2008-07-31
申请号：US11964493
申请日：2007-12-26
申请人： Michael J. Hadd , Yuanwei Chen , Yan Feng , Sengen Sen , Brian Seed
发明人： Michael J. Hadd , Yuanwei Chen , Yan Feng , Sengen Sen , Brian Seed
IPC分类号： A61K31/7048 , C07H17/04 , A61P3/10 , A61P3/04
CPC分类号： C07H17/04
摘要： Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
摘要翻译：提供对钠依赖性葡萄糖转运蛋白SGLT具有抑制作用的化合物。本发明还提供药物组合物，制备化合物的方法，合成中间体，以及独立地或与其它治疗剂组合使用化合物治疗受SGLT抑制影响的疾病和病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式